Streetwise Expert Interviews

Ajay Tandon Brandon Primack

Huge Growth Delivered in Very Small Packages: SeeThruEquity's Ajay Tandon and Brandon Primack

Institutional investors are, by and large, unable to own shares in companies with market valuations of less than $100 million, which means most sellside analysts don't write research on very small companies. The paradox: The micro-cap space is where investors can find the tenbaggers. That disconnect and its attendant irony are not lost on SeeThruEquity's Ajay Tandon and Brandon Primack. In this interview with The Life Sciences Report, Tandon and Primack discuss four companies nurturing seeds of dramatic growth that could materialize in the wake of upcoming catalysts.

(10/30/14) More >
Read More Streetwise Interviews

Japan Gives a Hug to the Cell Therapy Industry: R. Lee Buckler

Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview, former regenerative medicine consultant R. Lee Buckler talks about Japan's hospitable stance on proposed cell therapies. (10/22/14) More >

Newsletter Briefs

"We find CTH to be a very compelling story." (10/30/14) Cynapsus Therapeutics Inc. - The Life Sciences Report Interview with Brandon Primack More >

"The combination of DMPI's VAL-083 and radiation therapy showed an immediate survival benefit in glioblastoma multiforme." (10/30/14) DelMar Pharmaceuticals Inc. - The Life Sciences Report Interview with Brandon Primack More >

"Investors could be looking at a multibagger with MSLP." (10/22/14) MusclePharm Corp. - Mark Phillips, Seeking Alpha More >

"ATHX is putting boots on the ground in Japan to develop a strategy there." (10/22/14) Athersys Inc. - The Life Sciences Report Interview with R. Lee Buckler More >

"MSB is potentially in the pole position in Japan." (10/22/14) Mesoblast Ltd. - The Life Sciences Report Interview with R. Lee Buckler More >

"RXII's molecules are designed specifically to facilitate the uptake of their therapeutic payload." (10/8/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Keith Markey More >

"The patent for CPMA builds RNN's intellectual property fortress." (10/7/14) Rexahn Pharmaceuticals Inc. - Sharon di Stefano, Seeking Alpha More >

"The share buyback shows MSLP's new nature, one of avoiding dilution." (10/6/14) MusclePharm Corp. - Paulo Santos, Seeking Alpha More >

Expert Analysis

"INO will target product development within infectious disease." (10/21/14) Inovio Pharmaceuticals Inc. - Ram Selvaraju, Aegis Capital More >

"With 5% U.S. market share, CUR's NSI-566 is a potential $500M drug." (10/15/14) Neuralstem Inc. - Jason Napodano, Seeking Alpha More >

"Expanding into advanced wound care is a main growth driver for MDXG." (10/13/14) MiMedx Group Inc. - Bruce Jackson, Lake Street Capital Markets More >

"We think THLD could become profitable in 2016 based on revenue from sales of TH-302." (10/13/14) Threshold Pharmaceuticals Inc. - George Zavoico, MLV & Co More >

"CUR's forward progress of the NSI-556 trial for SCI is welcome news." (10/13/14) Neuralstem Inc. - Reni Benjamin, H.C. Wainwright & Co. More >

"CTH plans to complete three studies over Q4/14 and Q1/15." (10/9/14) Cynapsus Therapeutics Inc. - Ajay Tandon, SeeThruEquity More >

"Photos of RXII's treated patients showed significant improvement." (10/8/14) RXi Pharmaceuticals Corp. - Edward White, Laidlaw & Company More >

"We are increasing our price target for CTH." (10/2/14) Cynapsus Therapeutics Inc. - Nathan Cali, Noble Financial More >